[{"id":"d6659ed0-a160-442d-9ebc-6110d6f497a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03161652","created_at":"2022-07-22T08:56:46.266Z","updated_at":"2024-07-02T16:35:39.044Z","phase":"Phase 2","brief_title":"Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema","source_id_and_acronym":"NCT03161652","lead_sponsor":"Carmen Clapp","biomarkers":" PRL","pipe":"","alterations":" ","tags":["PRL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lucentis (ranibizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/24/2017","start_date":" 05/24/2017","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-08-25"},{"id":"0a7234f9-0a21-4819-ace5-9082ae1d4a9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02859441","created_at":"2021-01-18T14:02:14.116Z","updated_at":"2024-07-02T16:36:21.931Z","phase":"Phase 1/2","brief_title":"A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab","source_id_and_acronym":"NCT02859441","lead_sponsor":"National Eye Institute (NEI)","biomarkers":" VHL","pipe":" | ","alterations":" VHL mutation","tags":["VHL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VHL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fovista (pegpleranib) • Lucentis (ranibizumab)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 01/23/2017","start_date":" 01/23/2017","primary_txt":" Primary completion: 07/09/2019","primary_completion_date":" 07/09/2019","study_txt":" Completion: 07/09/2019","study_completion_date":" 07/09/2019","last_update_posted":"2021-11-01"},{"id":"34ae878a-fe01-42be-a429-886e5d6eeebf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00657202","created_at":"2021-01-18T02:26:54.908Z","updated_at":"2024-07-02T16:37:30.784Z","phase":"Phase 1","brief_title":"Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1","source_id_and_acronym":"NCT00657202","lead_sponsor":"Massachusetts General Hospital","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lucentis (ranibizumab)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 03/01/2008","start_date":" 03/01/2008","primary_txt":" Primary completion: 10/01/2009","primary_completion_date":" 10/01/2009","study_txt":" Completion: 12/01/2013","study_completion_date":" 12/01/2013","last_update_posted":"2016-07-07"}]